ライフサイエンスコーパス: haploidentical

1 re enrolled, 42 were HLA matched and 19 were haploidentical.

2 either mismatched unrelated (34%, P =.01) or haploidentical (21%, P =.002) patients.

3 sibling donor, 8; matched family donor, 13; haploidentical, 4; and unrelated, 45.

4 ling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical, 88% vs 19%), attributable to less infect

5 demonstrated in patients with AML undergoing haploidentical allogeneic HSCT and was suggested not to

6 constitution, particularly in MHC-mismatched haploidentical alloSCTs in which T cell-depleted allogra

7 eport 3-year survival exceeding 90% by using haploidentical alphabeta+CD3+/CD19+-depleted allogeneic

8 19 patients, we transplanted 17, 14 from HLA-haploidentical and 3 from HLA-matched related donors.

9 f hematopoietic cell engraftment in both the haploidentical and class II-disparate strain combination

10 95% CI, 36-54) and 50% (95% CI, 47-53) after haploidentical and matched unrelated donor transplants (

11 In addition, peptide-treated mice in the haploidentical and MHC class II-mismatched strain combin

12 usion studies, including cells obtained from haploidentical and third-party donors, showed efficacy i

13 Haploidentical and umbilical cord blood donations may be

14 Related HLA-haploidentical blood or marrow transplantation (BMT) wit

15 ances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BM

16 nors, one patient received a T-cell depleted haploidentical BM, and one patient received a non-T-cell

17 ated with 400 muCi (90)Y-DOTA-30F11, CY, and haploidentical BMT were cured and lived >200 days.

18 ultiple hematopoietic lineages 28 days after haploidentical BMT with 69.3 +/- 14.1%, 75.6 +/- 20.2%,

19 tively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this

20 efine outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hema

21 RIT-mediated haploidentical BMT without TBI may increase treatment op

22 tion despite having received T cell-depleted haploidentical BMT.

23 an donor origin CD8(+) cells) 6 months after haploidentical BMT.

24 ined immune deficiency (SCID) patients given haploidentical bone marrow (BM), lesions in humoral immu

25 the 11 patients who could be evaluated, the haploidentical bone marrow cells engrafted.

26 ormal weight gain, the decision for SCT from haploidentical bone marrow or peripheral blood was made.

27 es or bone marrow failure (BMF) who received haploidentical bone marrow transplantation (BMT) after e

28 Haploidentical bone marrow transplantation (BMT) with 30

29 ine A (CSA) to promote chimerism in a murine haploidentical bone marrow transplantation model.

30 ockade of B7/CD28 costimulation allows human haploidentical bone marrow transplantation without graft

31 renatally and successfully transplanted with haploidentical bone marrow.

32 months after kidney transplant from her HLA-haploidentical brother.

33 and GVHD-associated immune dysfunction in a haploidentical CBD2F1 (H2kxd) --> B6D2F1 (H2bxd) strain

34 greater challenge to the transplantation of haploidentical cells than thalassemia.

35 Lymphocytes from the peptide-treated haploidentical chimeric mice also displayed donor-specif

36 rs more frequently in patients receiving HLA-haploidentical compared with HLA-identical sibling trans

37 VHD (30% vs 53%, P < .0001) were lower after haploidentical compared with matched unrelated donor tra

38 , day 30 neutrophil recovery was lower after haploidentical compared with matched unrelated donor tra

39 us-host disease prophylaxis, and 1.5 x 10(7) haploidentical donor bone marrow cells (day 0).

40 vs 54%; P < .003), although in unconditioned haploidentical donor HCT, nonengraftment was a major pro

41 Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using

42 Furthermore, haploidentical donor memory CD8 T cells undergoing in vi

43 n support administration of large numbers of haploidentical donor T cells, resulting in rapid immune

44 ion (KT) after a previous HSCT from the same haploidentical donor typically received short-term immun

45 , respectively (P < .05 for those undergoing haploidentical donor v MRD or MUD transplantation).

46 CT from matched unrelated (66%; P < .05) and haploidentical donors (43%; P < .001).

47 Alternative donor selection using haploidentical donors and posttransplantation cyclophosp

48 of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood.

49 T-cell-replete grafts from haploidentical donors using post-transplantation cycloph

50 We compared outcomes of alloHCT using haploidentical donors with those of transplantation usin

51 alternative donors, including cord blood and haploidentical donors, are highlighted, and we discuss r

52 rs or T-cell-depleted marrow stem cells from haploidentical donors, with whom there is a single haplo

53 sible and have limited the use of mismatched haploidentical donors.

54 ntemporaneously at a single center (53 using haploidentical donors; 117, MRDs; 101, MUDs) were compar

55 tation platform using related, including HLA-haploidentical, donors for patients with sickle cell dis

56 In the majority of patients, early haploidentical engraftment was replaced by durable engra

57 ulated, G-CSF-primed BM transplantation from haploidentical family donor provides very encouraging re

58 ted, G-CSF-primed BM transplantation from an haploidentical family donor.

59 ogenitor cell (HPC) transplantation from HLA-haploidentical family donors.

60 ies underwent blood HPC transplantation from haploidentical family donors.

61 Nonmyeloablative therapy using haploidentical family member donors is feasible because

62 rd blood (UCB) and CD34(+) stem cells from a haploidentical family member.

63 who were recipients of a PMRD allo-BMT from haploidentical family members following conditioning the

64 Transplant from haploidentical family members is indicated for patients

65 15 HLA genotypically identical siblings, 14 haploidentical family members, and 5 unrelated donors.

66 ismatched unrelated grafts (45%, P =.01) and haploidentical grafts (42%, P =.001) compared with recip

67 nipulated (without ex vivo T-cell depletion) haploidentical grafts combined with enhanced posttranspl

68 cs in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature

69 nancy and those receiving mismatched related/haploidentical grafts, were 80% (+/-6%) and 77.7% (+/-6.

70 d unrelated grafts versus those who received haploidentical grafts.

71 28-day platelet recovery was delayed in the haploidentical group compared with the MSD group (63% v

72 The haploidentical group received graft-versus-host disease

73 post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell tra

74 sibling donor may have better outcomes than haploidentical (haplo) HSCT.

75 rug resistance was exclusively identified in haploidentical (haplo)-HSCT recipients receiving preempt

76 e graft sources, umbilical cord blood (UCB), haploidentical (haplo)-related donor, and mismatched unr

77 tical unfractionated and T cell-depleted HLA haploidentical, has been very successful in effecting im

78 eplacing total body irradiation (TBI) before haploidentical HCT in a murine model.

79 ld be applicable to major histocompatibility haploidentical HCT without excessive nonhematologic regi

80 Related donor haploidentical hematopoietic cell transplantation (Haplo

81 r in a canine model of dog leukocyte antigen-haploidentical hematopoietic cell transplantation (HCT).

82 Nine additional animals received haploidentical hematopoietic cell transplantation follow

83 mplex (MHC)-defined miniature swine received haploidentical hematopoietic cell transplantation follow

84 All animals conditioned for haploidentical hematopoietic cell transplantation using

85 immune reconstitution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo

86 tiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patien

87 Studies of haploidentical hematopoietic stem cell transplantation (

88 isease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (

89 onsecutive SCID-X1 patients having undergone haploidentical hematopoietic stem cell transplantation (

90 tracked TSCM dynamics in patients undergoing haploidentical hematopoietic stem cell transplantation (

91 delta T lymphocytes up to 7 months after HLA-haploidentical hematopoietic stem cell transplantation (

92 ren with nonmalignant disorders received HLA-haploidentical hematopoietic stem cell transplantation (

93 Haploidentical hematopoietic stem cell transplantation f

94 hese findings have important implications in haploidentical hematopoietic stem cell transplantation i

95 ractionated HLA-identical or T cell-depleted haploidentical hematopoietic stem cell transplantation,

96 Recent analysis of haploidentical hematopoietic transplantations has shown

97 antiviral and antileukemia effects after HLA-haploidentical hematopoietic transplants depleted of alp

98 tigated the role of donor activating KIRs in haploidentical hematopoietic transplants for acute leuke

99 ed chimeras and recipients of MHC-matched or haploidentical HSCs with a shared MHC haplotype had T-de

100 nded donor NK cells infused before and after haploidentical HSCT for high-risk myeloid malignancies.

101 loped chronic kidney failure after receiving haploidentical HSCT from his father for the treatment of

102 developed a 2-step myeloablative approach to haploidentical HSCT in which 27 patients conditioned wit

103 restingly, this advantage of gene therapy vs haploidentical HSCT seems to be independent of the exist

104 lantation from the same donor after previous haploidentical HSCT with a corticosteroid taper alone.

105 igh doses of ex vivo-expanded NK cells after haploidentical HSCT without adverse effects, increased G

106 eic HSCT and might also not be restricted to haploidentical HSCT.

107 be an equal, if not superior, alternative to haploidentical HSCT.

108 ations could facilitate viral control in the haploidentical infant.

109 (HCT) regimen in dog leukocyte antigen (DLA)-haploidentical littermate recipients consisting of 450 c

110 in four control living unrelated and two HLA haploidentical living-related donor recipient pairs, whe

111 BMT from human leukocyte antigen-mismatched, haploidentical living-related donors after modified nonm

112 sm and engraftment can be established across haploidentical major histocompatibility complex barriers

113 from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood tran

114 nd 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood.

115 e engraftment of dog leukocyte antigen (DLA)-haploidentical marrow following a single dose of 9.2 Gy

116 schedule with the exception of recipients of haploidentical marrow grafts, who received antithymocyte

117 nt-specific CTLs enhanced engraftment of DLA-haploidentical marrow in 9 of 11 evaluable recipients (P

118 ting, only 4 of 11 control recipients of DLA-haploidentical marrow without added CTLs engrafted.

119 of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent

120 ow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who r

121 mained abnormal in many of the recipients of haploidentical marrow.

122 fference; (2) (B6xDBA/2)F1 --> (B6xCBA)F1, a haploidentical MHC combination; and (3) B6.C-H2bm12 -->

123 transplantations; group 3 (n = 2) underwent haploidentical MHC-mismatched heart/kidney transplantati

124 i-tumor immune responses, the maintenance of haploidentical microchimerism may impart an allogeneic e

125 tibility antigen-mismatched as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenido

126 iated major histocompatibility complex (MHC)-haploidentical murine bone marrow transplantation (BMT)

127 Using a clinically relevant haploidentical murine transplantation model, we showed t

128 (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3).

129 ted 917 adult lymphoma patients who received haploidentical (n = 185) or HLA-matched unrelated donor

130 ults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated d

131 r genotypically DLA-identical (n = 9) or DLA-haploidentical (n = 9).

132 the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after

133 Haploidentical natural killer (NK) cell infusions can in

134 n of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for A

135 These findings suggest that haploidentical NK cells can persist and expand in vivo a

136 Because most patients have access to a haploidentical, one haplotype-mismatched donor, we have

137 but when a matched donor is not available, a haploidentical or mismatched unrelated donor (mMUD) can

138 We sought to evaluate the outcomes of haploidentical or mMUD HSCT after depleting GvHD-causing

139 (+)TCRalphabeta(+) and CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable al

140 Graft failure, 43% in haploidentical pairs, remains a major obstacle but may b

141 regulation was found in the remaining seven haploidentical pairs.

142 tested (7/7), and one half (9/18) of the HLA haploidentical pairs.

143 igen-identical or rigorously T cell-depleted haploidentical parental bone marrow transplantation (BMT

144 of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-iden

145 from the most readily available source: the haploidentical, partially mismatched, related donor.

146 ed unrelated patients (26%, P =.014) than in haploidentical patients (42%).

147 Of the 57 haploidentical patients, there were 33 males and 24 fema

148 All nine DLA-haploidentical recipients of PBSC developed fatal hypera

149 Haploidentical recipients received calcineurin inhibitor

150 Haploidentical recipients received posttransplant cyclop

151 nt (CCR5(-/-)) donor cells to nonconditioned haploidentical recipients resulted in reduced donor cell

152 cGy TBI with postgrafting MMF/CSP in 44 DLA-haploidentical recipients using eight different regimens

153 genotypically identical sibling (GIS) or HLA-haploidentical related (HIR) donors between September 16

154 ed double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow)

155 a underwent bone-marrow transplantation from haploidentical related donors sharing at least one HLA A

156 s such as mismatched adult unrelated donors, haploidentical related donors, and umbilical cord blood

157 with a low risk of complications, even with haploidentical related donors.

158 ukocyte antigen (HLA)- haplotype mismatched (haploidentical) related donors, suggesting that this pro

159 n leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bone marrow transplantatio

160 Here, we test haploidentical, related-donor NK-cell infusions in a non

161 ative using an URD, umbilical cord blood, or haploidentical-related donors; outcomes are either compa

162 stem cell transplantation (HSCT) from an HLA-haploidentical relative (haplo-HSCT) is a suitable optio

163 ors were HLA-identical siblings (n = 1,224); haploidentical relatives mismatched for one (n = 238) or

164 e of chronic rejection in living related one-haploidentical renal transplants in pediatric patients.

165 safely used to improve T-cell recovery after haploidentical SCT and may broaden the applicability of

166 lative preparative therapy with MEDI-507 and haploidentical SCT have led to the reliable induction of

167 se levels into recipients of T-cell-depleted haploidentical SCT.

168 l conditioning regimens, particularly in the haploidentical setting, justify further evaluation.

169 e and leads to tolerance toward the VCA in a haploidentical setting.

170 ), HLA-mismatched unrelated (n = 3), and HLA haploidentical sibling (n = 1).

171 , supported with purified CD34+ cells from a haploidentical sibling.

172 ery high-risk patients receiving combination haploidentical single-unit cord blood transplants, we ha

173 artially human leukocyte antigen-matched and haploidentical stem cell grafts (n = 13), without induci

174 lymphocyte reconstitution limits the use of haploidentical stem cell transplantation (SCT) because i

175 Poor immune reconstitution after haploidentical stem cell transplantation results in a hi

176 T cells from healthy donor and patient after haploidentical stem cell transplantation.

177 itiated a clinical trial of nonmyeloablative haploidentical stem-cell transplantation (SCT) using MED

178 te of graft rejection in patients undergoing haploidentical stem-cell transplantation.

179 hance immune reconstitution in recipients of haploidentical stem-cell transplants.

180 kedly reduces GvHD in a clinically relevant, haploidentical strain combination, while permitting anti

181 Transplantation of HLA-identical or haploidentical T cell-depleted allogeneic bone marrow (B

182 ients with increasing numbers of alloreplete haploidentical T cells expressing the inducible caspase

183 xt of CY tolerization, a high, fixed dose of haploidentical T cells was associated with encouraging o

184 donor, survival was best among recipients of haploidentical T-cell-depleted transplants in the absenc

185 Although haploidentical transplant modalities are based mainly on

186 Mismatched/haploidentical transplant provides an alternative approa

187 ment in the major histocompatibility complex-haploidentical transplant setting.

188 t of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell

189 donors, suggesting that this procedure makes haploidentical transplantation available in all transpla

190 -cell population in the early days following haploidentical transplantation combined with pt-Cy and p

191 Recent advances have made haploidentical transplantation for leukemia feasible, bu

192 imulation with costimulatory blockade before haploidentical transplantation has demonstrated early pr

193 ncluded in the donor selection algorithm for haploidentical transplantation in children with acute ly

194 Today human leukocyte antigen-haploidentical transplantation is a feasible option for

195 The use of sirolimus in haploidentical transplantation is now being explored as

196 eukemia who received human leukocyte antigen-haploidentical transplantation of ex vivo T-cell-deplete

197 relapse in offspring with leukemia after HLA-haploidentical transplantation of maternal hematopoietic

198 Haploidentical transplantation performed using T-cell-re

199 ocytes in animal models, tomorrow's world of haploidentical transplantation will focus on new "design

200 suggest that reduced-intensity conditioning haploidentical transplantation with posttransplant cyclo

201 ts that survival for patients with AML after haploidentical transplantation with posttransplant cyclo

202 ted grafts substantially extended the use of haploidentical transplantation with results than even ri

203 Conclusion PB and BM grafts are suitable for haploidentical transplantation with the post-transplant

204 Severe GVHD developed after haploidentical transplantation without prophylaxis, char

205 Haploidentical transplantation would serve to extend the

206 For patients undergoing MRD, MUD, and haploidentical transplantation, 24-month cumulative inci

207 e 1990s saw what had been major drawbacks of haploidentical transplantation, ie, very strong host-ver

208 In T cell-depleted haploidentical transplantation, recent advances were mad

209 In HLA-haploidentical transplantation, we reported that donor-d

210 oring the GVL effect after HLA-A2-mismatched haploidentical transplantation.

211 man leukocyte antigen haplotype mismatched ("haploidentical") transplantation, its translation to cli

212 e emerging data for alternate donor (cord or haploidentical) transplantation in AA has provided addit

213 1 CD3(+)TCR alphabeta/CD19 depleted parental haploidentical transplants were performed.

214 In contrast, of the nine HLA haploidentical transplants with bidirectional regulation

215 Of the nine HLA haploidentical transplants with unidirectional or no pre

216 The study included a total of 28 haploidentical transplants, each with 2 to 5 HLA allele

217 Similarly, relative to haploidentical transplants, risk of chronic GVHD was hig

218 experienced primary graft failure had second haploidentical transplants.

219 well as URD with ATG (P = .01), relative to haploidentical transplants.

220 .21) or URD with ATG (P = .16), relative to haploidentical transplants.

221 ch) received cyclophosphamide, MEDI-507, and haploidentical unmanipulated bone marrow (n=8) or ex viv

222 Haploidentical, unmanipulated, G-CSF-primed bone marrow

223 variate analysis was 8%, 12%, and 17% in the haploidentical, URD without ATG, and URD with ATG groups

224 sion at 3 years was 36%, 28%, and 36% in the haploidentical, URD without ATG, and URD with ATG groups